Literature DB >> 14661927

In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection.

Hanlan Liu1, Chantel Sabus, Guy T Carter, Chao Du, Alex Avdeef, Mark Tischler.   

Abstract

PURPOSE: This study compares the use of UV-VIS detection with liquid chromatography/mass spectrometry (LC/MS) detection for the PAMPA (Parallel Artificial Membrane Permeability Assay) permeability determination of compounds in the drug discovery stage. LC/MS detection offers a selective and sensitive method for the determination of the PAMPA permeability for compounds that do not contain a UV chromophore or possess a low UV extinction coefficient. To enhance the reliability of our permeability measurements for compounds with low aqueous solubility, we demonstrated the use of LC/MS detection as a means for facilitating the study of solubilizing agents to enhance aqueous solubility that normally would interfere with UV-VIS detection. In doing so, the PAMPA assay can be expanded to study the in vitro permeability of poorly water soluble compounds and evaluate the effects of solubilizers' on the membrane permeability of different compounds. This might be useful in selecting solubilizers for poorly water soluble compounds to be used for further in vivo studies.
METHODS: A diverse set of 20 drugs using UV-VIS detection were compared with data using LC/MS detection. A PAMPA screening method was designed which used solubilizers (Brij 35, Cremophor EL, ethanol, and Tween 80) for compounds with low aqueous solubility. The stability of the artificial membrane was determined using various solubilizer concentrations (0.1-5% w/v) to ensure the phospholipid membrane was not disrupted. Two compounds, amiodarone and miconazole, with low aqueous solubility yielding an undetected response in the PAMPA assay using UV-VIS detection were subjected to the different solubilizing agents and their PAMPA permeability was measured using LC/MS detection.
RESULTS: Most of the compounds showed similar PAMPA permeability using the two detection systems. However, for compounds lacking a UV chromophore or with a low UV extinction coefficient, LC/MS was the detection method of choice for determination of PAMPA permeability values. LC/MS also gave reliable quantification data for compounds containing impurities, as well as compounds that were not stable during the assay. Although many solubilizers were found to interfere with UV-VIS detection, the LC/MS approach was applicable to determine the permeability values of compounds with normally low aqueous solubility.
CONCLUSIONS: LC/MS detection offered greater sensitivity and selectivity as compared with UV-VIS detection for the PAMPA assay. With this added versatility in detection, PAMPA can be used in both discovery and pre-formulation applications, which has not been described before.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661927     DOI: 10.1023/b:pham.0000003380.44755.5a

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  Fluorometric screening for metabolism-based drug--drug interactions.

Authors:  C L Crespi; D M Stresser
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Jul-Aug       Impact factor: 1.950

2.  Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs.

Authors:  P Poulin; K Schoenlein; F P Theil
Journal:  J Pharm Sci       Date:  2001-04       Impact factor: 3.534

Review 3.  Prediction of toxicity from chemical structure.

Authors:  M D Barratt
Journal:  Cell Biol Toxicol       Date:  2000       Impact factor: 6.691

Review 4.  Evaluation of the BBMEC model for screening the CNS permeability of drugs.

Authors:  K W Otis; M L Avery; S M Broward-Partin; D K Hansen; H W Behlow; D O Scott; T N Thompson
Journal:  J Pharmacol Toxicol Methods       Date:  2001 Jan-Feb       Impact factor: 1.950

5.  Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors.

Authors:  Y H Zhao; J Le; M H Abraham; A Hersey; P J Eddershaw; C N Luscombe; D Butina; G Beck; B Sherborne; I Cooper; J A Platts; D Boutina
Journal:  J Pharm Sci       Date:  2001-06       Impact factor: 3.534

6.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.

Authors:  J P Jones; M He; W F Trager; A E Rettie
Journal:  Drug Metab Dispos       Date:  1996-01       Impact factor: 3.922

7.  High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.

Authors:  F Wohnsland; B Faller
Journal:  J Med Chem       Date:  2001-03-15       Impact factor: 7.446

8.  Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in Piper methysticum Forst.

Authors:  A Avdeef; M Strafford; E Block; M P Balogh; W Chambliss; I Khan
Journal:  Eur J Pharm Sci       Date:  2001-12       Impact factor: 4.384

9.  Functional connections between cells as revealed by dye-coupling with a highly fluorescent naphthalimide tracer.

Authors:  W W Stewart
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

10.  On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.

Authors:  D F Lewis
Journal:  Biochem Pharmacol       Date:  2000-08-01       Impact factor: 5.858

View more
  12 in total

1.  A novel design of artificial membrane for improving the PAMPA model.

Authors:  Xiaoxi Chen; Anthony Murawski; Karishma Patel; Charles L Crespi; Praveen V Balimane
Journal:  Pharm Res       Date:  2008-01-10       Impact factor: 4.200

2.  Solubility-excipient classification gradient maps.

Authors:  Alex Avdeef; Stefanie Bendels; Oksana Tsinman; Konstantin Tsinman; Manfred Kansy
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

3.  PAMPA - excipient classification gradient map.

Authors:  Stefanie Bendels; Oksana Tsinman; Björn Wagner; Dana Lipp; Isabelle Parrilla; Manfred Kansy; Alex Avdeef
Journal:  Pharm Res       Date:  2006-10-20       Impact factor: 4.200

Review 4.  Permeability barriers of Gram-negative pathogens.

Authors:  Helen I Zgurskaya; Valentin V Rybenkov
Journal:  Ann N Y Acad Sci       Date:  2019-06-04       Impact factor: 5.691

5.  Ladderane phospholipids form a densely packed membrane with normal hydrazine and anomalously low proton/hydroxide permeability.

Authors:  Frank R Moss; Steven R Shuken; Jaron A M Mercer; Carolyn M Cohen; Thomas M Weiss; Steven G Boxer; Noah Z Burns
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-27       Impact factor: 11.205

6.  Impact of Micellar Surfactant on Supersaturation and Insight into Solubilization Mechanisms in Supersaturated Solutions of Atazanavir.

Authors:  Anura S Indulkar; Huaping Mo; Yi Gao; Shweta A Raina; Geoff G Z Zhang; Lynne S Taylor
Journal:  Pharm Res       Date:  2017-03-28       Impact factor: 4.200

7.  Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles.

Authors:  Grace A Ledet; Richard A Graves; Elena Y Glotser; Tarun K Mandal; Levon A Bostanian
Journal:  Int J Pharm       Date:  2014-12-24       Impact factor: 5.875

8.  Improving tenoxicam solubility and bioavailability by cosolvent system.

Authors:  Ming-Kung Yeh; Li-Chien Chang; Andy Hong-Jey Chiou
Journal:  AAPS PharmSciTech       Date:  2009-02-18       Impact factor: 3.246

9.  A new PAMPA model proposed on the basis of a synthetic phospholipid membrane.

Authors:  Hui Yu; Qi Wang; Ying Sun; Ming Shen; He Li; Yourong Duan
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

10.  A New Generation of Arachidonic Acid Analogues as Potential Neurological Agent Targeting Cytosolic Phospholipase A2.

Authors:  Cheng Yang Ng; Srinivasaraghavan Kannan; Yong Jun Chen; Francis Chee Kuan Tan; Wee Yong Ong; Mei Lin Go; Chandra S Verma; Chian-Ming Low; Yulin Lam
Journal:  Sci Rep       Date:  2017-10-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.